Compass Pathways Plc ADR
Closed
10.32 -2.18
Overview
Share price change
24h
Min
10.01
Max
10.67
Income | 44M -94M |
|---|---|
Employees | 156 |
EBITDA | 91M -46M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +108.3% upside |
Next Earnings | 30 lip 2026 |
|---|
Market Cap | 696M 1.3B |
|---|---|
Previous open | 12.5 |
Previous close | 10.32 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Compass Pathways Plc ADR Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Compass Pathways Plc ADR Forecast
Price Target
By TipRanks
108.3% upside
12 Months Forecast
Average 22.83 USD 108.3%
High 70 USD
Low 12 USD
Based on 12 Wall Street analysts offering 12 month price targets forCompass Pathways Plc ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.